CR20140037A - Antagonistas trpm8 y su uso en tratamientos - Google Patents

Antagonistas trpm8 y su uso en tratamientos

Info

Publication number
CR20140037A
CR20140037A CR20140037A CR20140037A CR20140037A CR 20140037 A CR20140037 A CR 20140037A CR 20140037 A CR20140037 A CR 20140037A CR 20140037 A CR20140037 A CR 20140037A CR 20140037 A CR20140037 A CR 20140037A
Authority
CR
Costa Rica
Prior art keywords
treatments
trpm8
trpm8 antagonists
useful
antagonists
Prior art date
Application number
CR20140037A
Other languages
English (en)
Inventor
Kaustav Biswas
James Brown
Jian J Chen
Vijay Keshav Gore
Scott Harried
Daniel B Horne
Matthew R Kaller
Qingyian Liu
Vu Van Ma
Holger Monenschein
Thomas T Nguyen
Chester Chenguang Yuan
Jean David J St Jr
Wenge Zhong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20140037A publication Critical patent/CR20140037A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Los compuestos de la fórmula I son útiles como antagonistas de TRPM8. Tales compuestos son útiles al tratar un número de trastornos y afecciones mediados por TRPM8 y pueden usarse para preparar medicamentos y composiciones farmacéticas útiles para tratar tales trastornos y afecciones.
CR20140037A 2011-06-24 2014-01-24 Antagonistas trpm8 y su uso en tratamientos CR20140037A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161500843P 2011-06-24 2011-06-24

Publications (1)

Publication Number Publication Date
CR20140037A true CR20140037A (es) 2014-03-13

Family

ID=46384521

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140037A CR20140037A (es) 2011-06-24 2014-01-24 Antagonistas trpm8 y su uso en tratamientos

Country Status (22)

Country Link
US (3) US8710043B2 (es)
EP (1) EP2723717A2 (es)
JP (1) JP2014527511A (es)
KR (1) KR20140045507A (es)
CN (1) CN103906733A (es)
AP (1) AP2013007331A0 (es)
AR (1) AR086750A1 (es)
AU (1) AU2012272895B2 (es)
BR (1) BR112013033316A2 (es)
CA (1) CA2839699A1 (es)
CL (1) CL2013003715A1 (es)
CO (1) CO6852073A2 (es)
CR (1) CR20140037A (es)
EA (1) EA201490152A1 (es)
MA (1) MA35271B1 (es)
MX (1) MX2013015274A (es)
MY (1) MY157429A (es)
PE (1) PE20140868A1 (es)
TN (1) TN2013000529A1 (es)
TW (2) TW201429948A (es)
UY (1) UY34160A (es)
WO (1) WO2012177893A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
JP6770511B2 (ja) * 2014-09-29 2020-10-14 ザ スクリプス リサーチ インスティテュート 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
CN113398124A (zh) * 2016-06-13 2021-09-17 田边三菱制药株式会社 用于治疗或预防血管舒缩症状的组合物
SG11201912397RA (en) 2017-06-22 2020-01-30 Curadev Pharma Ltd Small molecule modulators of human sting
EP3642184A1 (en) * 2017-06-22 2020-04-29 Curadev Pharma Limited Small molecule modulators of human sting
TW201929855A (zh) 2017-12-19 2019-08-01 日商田邊三菱製藥股份有限公司 用於治療或預防血管舒縮症狀的組成物及方法
EP3768659B1 (en) * 2018-03-21 2023-07-19 Piramal Pharma Limited An improved asymmetric synthesis of alpha-(diarylmethyl) alkyl amines
JP2021522176A (ja) * 2018-04-18 2021-08-30 ピラマル ファーマ リミテッド アルファ−分岐キラルアミンの改善された不斉合成
CN110981795B (zh) * 2019-12-18 2021-02-12 武汉世纪久海检测技术有限公司 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法
JP7323723B2 (ja) 2020-06-17 2023-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
AU2021292061A1 (en) * 2020-06-17 2023-01-19 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as Nav1.8 inhibitors
MX2022015580A (es) * 2020-06-17 2023-01-24 Merck Sharp & Dohme Llc 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.
CN115108980B (zh) * 2022-06-22 2023-06-16 济南大学 一种2-甲基喹啉类化合物的4号位酰基化衍生物的制备方法

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483250A (en) * 1949-09-27 Tt a it tt
DE2417763A1 (de) 1974-04-11 1975-10-30 Bayer Ag Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2428673A1 (de) 1974-06-14 1976-01-02 Bayer Ag Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS53141271U (es) 1977-04-14 1978-11-08
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5081131A (en) 1986-01-13 1992-01-14 American Cyanamid Company Omega-((hetero)alkyl)benz(cd)-indol-2-amines
US5223499A (en) 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
AU640016B2 (en) 1990-05-30 1993-08-12 Imperial Chemical Industries Plc Hydroquinazoline derivatives
US5380721A (en) 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
WO1992012973A1 (fr) 1991-01-23 1992-08-06 Nippon Kayaku Kabushiki Kaisha Derive de chromane
ES2036926B1 (es) 1991-08-08 1994-01-16 Uriach & Cia Sa J "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE4138819A1 (de) 1991-11-26 1993-05-27 Basf Ag Hydroxypyridoncarbonsaeureamide, deren herstellung und verwendung
GB9127041D0 (en) 1991-12-20 1992-02-19 Fujisawa Pharmaceutical Co New use
FR2692895A1 (fr) 1992-06-26 1993-12-31 Adir Nouveaux 1-oxo 2,4,5,6-tétrahydro 2,3,7-triazaphénalènes leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
EP0653434A1 (en) 1993-11-12 1995-05-17 Tanabe Seiyaku Co., Ltd. Glucosamine derivative, process for preparing the same and synthetic intermediate thereof
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
AU4432496A (en) 1994-12-23 1996-07-19 Dr. Karl Thomae Gmbh Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
JPH11501934A (ja) 1995-03-14 1999-02-16 シャスカン，エドワード・ジー ニコチニルアラニンと、グリシン抱合の阻害薬又はビタミンｂ６とを含む組成物
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
IL117940A (en) 1995-04-19 2003-06-24 Kumiai Chemical Industry Co Benzylsulfide derivatives, process for their production and insecticide compositions containing them
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
DE19523087A1 (de) 1995-06-26 1997-01-02 Bayer Ag 1,3-Oxa(thia)zin-Derivate
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
GB9525828D0 (en) 1995-12-18 1996-02-21 Bayer Ag Use of hetarylacetic acid derivatives
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
US6075029A (en) 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
EP1049691B1 (en) 1998-01-21 2004-02-18 Banyu Pharmaceutical Co., Ltd. Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
CA2334032A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US5910595A (en) 1998-06-26 1999-06-08 Salsbury Chemicals, Inc. Process for preparing oximidazoles
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
WO2000035889A1 (fr) 1998-12-11 2000-06-22 Sankyo Company, Limited Benzylamines substituees
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
US6200993B1 (en) 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
TR200002099A3 (tr) 1999-07-22 2001-06-21 Sankyo Company Limited Siklobüten türevleri, bunlarin hazirlanmasi ve terapötik kullanimlari
GB9919588D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
BR0013593A (pt) 1999-09-01 2002-05-07 Unilever Nv Método para alvejar manchas de tecido
CA2383596A1 (en) 1999-09-01 2001-03-08 Unilever Plc Composition and method for bleaching a substrate
BR0013592A (pt) 1999-09-01 2002-05-07 Unilever Nv Embalagem comercial para alvejar manchas de tecido em um licor de lavagem aquoso, e, uso da mesma
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
ATE271049T1 (de) 1999-11-10 2004-07-15 Takeda Chemical Industries Ltd Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
EP1254114A2 (en) 2000-01-28 2002-11-06 Melacure Therapeutics AB Melanocortin receptor agonists and antagonists
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020019527A1 (en) 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
AU2001259218A1 (en) 2000-04-27 2001-11-07 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
JP2001354563A (ja) 2000-06-09 2001-12-25 Sankyo Co Ltd 置換ベンジルアミン類を含有する医薬
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6417367B1 (en) 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
US20030050211A1 (en) 2000-12-14 2003-03-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Enzymatic detergent compositions
WO2002051396A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions pharmaceutiques contenant des derives de cyclobutene
JP2002302439A (ja) 2001-01-19 2002-10-18 Sankyo Co Ltd シクロブテン誘導体を含有する回腸型胆汁酸トランスポーター阻害剤
US20040106635A1 (en) 2001-03-29 2004-06-03 Iwao Takamuro Spiroisoquinoline compound, a method for preparing the same and an intermediate thereof
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
MY130373A (en) 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
US6596718B1 (en) 2001-11-27 2003-07-22 Hoffmann-La Roche Inc. 7-Morpholin-4yl-benzothiazole amide derivatives
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
TWI261053B (en) 2001-12-06 2006-09-01 Novartis Ag Amidoacetonitrile compounds, their preparation, compositions and use as pesticides
SE0104248D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
EA007328B1 (ru) 2002-03-28 2006-08-25 Апплайд Резеч Системз Арс Холдинг Н. В. Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f
AU2003221706B2 (en) 2002-04-11 2008-02-28 Merck Sharp & Dohme Corp. 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
FR2838739B1 (fr) 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
BR0309522A (pt) 2002-04-26 2005-02-09 Ishihara Sangyo Kaisha Compostos piridina ou sais destes e herbicidas contendo os mesmos
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
FR2842805A1 (fr) 2002-07-29 2004-01-30 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide,leur preparation et leur application et therapeutique
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
JP2004115450A (ja) 2002-09-27 2004-04-15 Tanabe Seiyaku Co Ltd 医薬組成物
WO2004039795A2 (en) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
JP4261884B2 (ja) 2002-11-26 2009-04-30 株式会社ネオス 水溶性金属加工油剤組成物
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
AU2003290333A1 (en) 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of imidazo(1,5-a)pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
CA2524352A1 (en) 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Substituted pyrimidine derivatives
EP1660454A1 (en) 2003-07-07 2006-05-31 Vernalis (R&D) Limited Azacyclic compounds as inhibitors of sensory neurone specific channels
CA2573951A1 (en) 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
US7094791B2 (en) 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
CA2537364A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use for the preparation of medicament against 5-ht2a receptor-related disorders
GB0320983D0 (en) 2003-09-08 2003-10-08 Biofocus Plc Compound libraries
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
BRPI0415179A (pt) * 2003-10-07 2006-11-28 Renovis Inc derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
WO2005042524A1 (en) 2003-10-30 2005-05-12 Virochem Pharma Inc. Pyridine carboxamide and methods for inhibiting hiv integrase
EP1716137A1 (en) 2004-02-04 2006-11-02 Pfizer Products Incorporated Substituted quinoline compounds
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
EP1720855A4 (en) 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
US7423147B2 (en) 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
DE102004022897A1 (de) 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2005115374A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for therapeutic use
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
DE102004031323A1 (de) 2004-06-29 2006-01-19 Bayer Cropscience Ag Substituierte Pyridazincarboxamide und Derivate hiervon
KR20070063526A (ko) * 2004-08-30 2007-06-19 뉴로메드 파머큐티칼즈 리미티드 칼슘 채널 차단제인 우레아 유도체
AR050926A1 (es) 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
KR100677149B1 (ko) 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
JPWO2006057448A1 (ja) 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
JP2008524325A (ja) * 2004-12-21 2008-07-10 アストラゼネカ アクチボラグ 複素環式ＭＣＨｒ１アンタゴニストと療法におけるその使用
US20080207677A1 (en) 2004-12-31 2008-08-28 Gpc Biotech Ag Napthyridine Compounds As Rock Inhibitors
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
WO2006094246A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-arylmethyl benzamide sirtuin modulators
JP5007788B2 (ja) 2005-05-16 2012-08-22 日産化学工業株式会社 ジヒドロアゾール置換ベンズアミド化合物及び有害生物防除剤
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
BRPI0613535A2 (pt) 2005-06-02 2011-01-18 Bayer Cropscience Ag derivados de heteroarila substituìda por fenilalquila
US8163956B2 (en) 2005-06-13 2012-04-24 Merck Sharp & Dohme Corp. Inhibitors of GLYT1 transporters
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
EP1904472A1 (en) 2005-07-15 2008-04-02 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
EP1764098A1 (en) 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
WO2007054302A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl ureas for treating diabetic neuropathy
ATE493986T1 (de) 2005-11-10 2011-01-15 Bayer Schering Pharma Ag Diarylharnstoffe zur behandlung von pulmonaler hypertonie
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
CA2633417A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
CA2633411A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
WO2007086799A1 (en) 2006-01-27 2007-08-02 Astrazeneca Ab Amide substituted quinolines
US20100234351A1 (en) 2006-02-23 2010-09-16 Takeda Pharmaceutical Company Limited Fused nitrogen-comprising heterocyclic compound
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
MX2008013238A (es) * 2006-04-12 2008-10-21 Merck & Co Inc Antagonistas de los canales de calcio de tipo t de piridil amida.
MX2008014953A (es) 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
GB0611152D0 (en) 2006-06-06 2006-07-19 Ucb Sa Therapeutic agents
WO2008003746A1 (en) 2006-07-06 2008-01-10 Bayer Cropscience Sa N-(4-pyridin-2-ylbutyl) carboxamide derivatives, their process of preparation and their use as fungicides
CN101611009A (zh) 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
AU2007287645B2 (en) * 2006-08-21 2012-11-08 F. Hoffmann-La Roche Ag DI-aromatic substituted amides as inhibitors for GlyT1
US7834023B2 (en) 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008056687A1 (fr) 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
AU2007321920A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
US20080221083A1 (en) 2006-11-20 2008-09-11 Matthias Hochgurtel Heterobicyclic metalloprotease inhibitors
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2008112156A1 (en) 2007-03-08 2008-09-18 Altiris Therapeutics Chemokine receptor modulators
CA2683581A1 (en) 2007-04-11 2008-10-23 Merck & Co., Inc. Cgrp receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
US8993588B2 (en) 2007-06-05 2015-03-31 Merck Sharp & Dohme Corp. Carboxamide heterocyclic CGRP receptor antagonists
JP2010533159A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
EP2188295A4 (en) 2007-08-10 2011-11-16 Crystalgenomics Inc PYRIDINE DERIVATIVES AND METHODS OF USE
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
WO2009038812A1 (en) 2007-09-20 2009-03-26 Amgen Inc. Condensed piperidine derivatives useful as vanilloid receptor ligands
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
WO2009072621A1 (ja) 2007-12-07 2009-06-11 Nissan Chemical Industries, Ltd. 置換ジヒドロアゾール化合物及び有害生物防除剤
AU2009225869B2 (en) 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
WO2009124962A2 (en) 2008-04-11 2009-10-15 Merck Serono S.A. Sulfonamides
DE102008019838A1 (de) 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US8377955B2 (en) 2008-06-12 2013-02-19 Merck, Sharp & Dohme, Corp. Branched 3- and 6-substituted quinolines as CGRP receptors antagonists
US20110263657A1 (en) 2008-06-25 2011-10-27 Bayer Schering Pharma Aktiengesellschaft Diaryl ureas for treating heart failure
US8653099B2 (en) * 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
CN101343313B (zh) 2008-09-03 2011-11-16 南京农业大学 一种葡萄糖二肽类化合物及其制备方法和用途
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
UY32525A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
RU2011148937A (ru) * 2009-05-01 2013-06-10 Раквалиа Фарма Инк. Производные сульфамоилбензойной кислоты в качестве антагонистов trpm8
CA2761639C (en) 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2010141330A1 (en) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
US20120245205A1 (en) 2009-07-29 2012-09-27 Delong Mitchell A Compositions and methods for inhibiting hair growth
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
JP2013516479A (ja) 2010-01-06 2013-05-13 ジョゼフ・ピー・エリコ 標的薬物を開発する方法および組成物
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011106632A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JPWO2011142359A1 (ja) 2010-05-10 2013-07-22 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
US8669252B2 (en) 2010-05-17 2014-03-11 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011147765A1 (de) 2010-05-27 2011-12-01 Bayer Cropscience Ag Pyridinylcarbonsäure derivate als fungizide
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
MX340488B (es) 2010-11-05 2016-07-08 Senomyx Inc Compuestos utiles como moduladores de trpm8.
PL3366688T3 (pl) 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
EP2651412A4 (en) 2010-12-14 2014-08-13 Beth Israel Hospital ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE
AU2010365740B2 (en) 2010-12-15 2015-12-24 Ppg Europe Bv Drier composition and use thereof
US20130324522A1 (en) 2010-12-17 2013-12-05 The Rockefeller University Insect odorant receptor antagonists
WO2012118850A1 (en) 2011-02-28 2012-09-07 Array Biopharma Inc. Serine/threonine kinase inhibitors
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.

Also Published As

Publication number Publication date
TW201429948A (zh) 2014-08-01
MX2013015274A (es) 2014-03-31
CL2013003715A1 (es) 2014-06-27
US8710043B2 (en) 2014-04-29
PE20140868A1 (es) 2014-07-18
US20130157996A1 (en) 2013-06-20
US20140171406A1 (en) 2014-06-19
WO2012177893A3 (en) 2013-06-13
US20140171639A1 (en) 2014-06-19
MY157429A (en) 2016-06-15
JP2014527511A (ja) 2014-10-16
US9096527B2 (en) 2015-08-04
EP2723717A2 (en) 2014-04-30
KR20140045507A (ko) 2014-04-16
CA2839699A1 (en) 2012-12-27
TWI448454B (zh) 2014-08-11
TN2013000529A1 (en) 2015-03-30
AU2012272895B2 (en) 2015-01-22
WO2012177893A2 (en) 2012-12-27
TW201311643A (zh) 2013-03-16
BR112013033316A2 (pt) 2017-01-31
AP2013007331A0 (en) 2013-12-31
EA201490152A1 (ru) 2014-05-30
UY34160A (es) 2012-08-31
MA35271B1 (fr) 2014-07-03
CN103906733A (zh) 2014-07-02
CO6852073A2 (es) 2014-01-30
AR086750A1 (es) 2014-01-22
AU2012272895A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
CR20140037A (es) Antagonistas trpm8 y su uso en tratamientos
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
GT201300266A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201400070A (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido.
CL2014002742A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) (divisional de solicitud 1291-2014)
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
UY35210A (es) Inhibidores de autotaxina
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
ECSP15013883A (es) Benzamidas
UY34285A (es) Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
CL2013002861A1 (es) Compuestos analogos de acido epoxieicosatrienoico, agonistas de eet; composicion farmaceutica; y uso de los compuestos para preparar medicamentos utiles para tratar hipertension y nefrotoxicidad inducida medicamentos, tal como cisplatino.
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY35410A (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
CR20130671A (es) Antagonistas de trpv4
UY34964A (es) Derivados de cromano como inhibidores del receptor transitorio potencial de la melastatina 8 (trpm8)
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
NI201500080A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3.